(Q36083211)

English

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

J-F Rossi

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

N Fegueux

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Z Y Lu

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

E Legouffe

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

C Exbrayat

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

M-C Bozonnat

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

R Navarro

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

E Lopez

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

P Quittet

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

J-P Daures

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

V Rouillé

11

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

T Kanouni

12

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

J Widjenes

13

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

B Klein

14

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

1 November 2005

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

36

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

771-779

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705138

0 references

Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Administration of plasmid DNA expressing human interleukin-6 significantly improves thrombocytopoiesis in irradiated mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Autologous and allogeneic stem cell transplantation in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Serum interleukin-6 levels during bone marrow transplantation: impact on transplant-related toxicity and engraftment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Interleukin-6 in human multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Cytokine-binding proteins: stimulating antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

2 October 2017

Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

27 July 2018

Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

27 July 2018

Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

27 July 2018

Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

27 July 2018

Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

27 July 2018

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

23 September 2018

Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

23 September 2018

Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

23 September 2018

Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

23 September 2018

Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

23 September 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705138

21 January 2018

Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034604

21 October 2018

Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705138

21 January 2018

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705138

21 January 2018

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://pubmed.ncbi.nlm.nih.gov/16113665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16113665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/16113665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6

1 reference

https://pubmed.ncbi.nlm.nih.gov/16113665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16113665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16113665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16113665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Age is not a prognostic variable with autotransplants for multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16113665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Total therapy with tandem transplants for newly diagnosed multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16113665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34(+)CD38(-/low) cells capable of repopulating severe combined immunodeficiency mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/16113665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16113665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association between high interleukin-6 levels and adverse outcome after autologous haemopoietic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/16113665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16113665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BMT.1705138

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36083211&oldid=1647920437"